Provided by Tiger Fintech (Singapore) Pte. Ltd.

KEYMED BIO-B

61.600
+1.8003.01%
Volume:1.55M
Turnover:94.93M
Market Cap:18.42B
PE:-28.60
High:63.000
Open:59.050
Low:59.050
Close:59.800
52wk High:80.000
52wk Low:27.050
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:1.99
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.154
ROE:-8.82%
ROA:-5.44%
PB:5.27
PE(LYR):-28.60
PS:19.28

Loading ...

HK Stock Connect Shareholding Changes | November 12

Stock News
·
Nov 12

Why Is Keymed Biosciences (SEHK:2162) Drawing Big-Name Support After Stapokibart’s Approval in China?

Simply Wall St.
·
Nov 06

HK Stock Movement | KEYMED BIO-B (02162) Rises Over 3% Against Market Trend as CM512 Phase I Trial for Atopic Dermatitis Meets All Endpoints

Stock News
·
Nov 05

HK Stock Movement | KEYMED BIO-B (02162) Surges Over 7% as Goldman Sachs Highlights Stapokibart's Potential to Establish Valuation Foundation

Stock News
·
Nov 03

Southbound Capital Flow Statistics (T+2) | November 3

Stock News
·
Nov 03

HK Stock Connect Shareholding Changes as of October 30

Stock News
·
Oct 30

Hong Kong Stocks Movement | Pharmaceutical Stocks Continue Multi-Day Decline Amid Short-Term External Environment Changes, Institutions Remain Optimistic About Long-Term Industry Development Trends

Stock News
·
Oct 14

Hong Kong Stock Movement | KEYMED BIO-B (02162) Surges Over 5% Intraday as First Dual-Antibody Drug CM336 Initiates Phase III Study

Stock News
·
Sep 22

Is There Still Potential in Keymed Biosciences After Shares Double in 2025?

Simply Wall St.
·
Sep 14

Hong Kong Stocks Alert | KEYMED BIO-B (02162) Surges Over 10% in Morning Session on Strong H1 Subcilizumab Commercial Performance and Robust Competitive Position in Atopic Dermatitis Market

Stock News
·
Sep 05

Bank of Communications International Raises KEYMED BIO-B Target Price to HK$78 as Core Products Accelerate Market Penetration in H1

Stock News
·
Aug 29

KeyMed Biosciences (02162.HK) Reports Strong Interim 2025 Results With Accelerated Commercialization and Robust R&D Momentum

THOMSON REUTERS
·
Aug 27

HK Movers | Biotech Stocks Decline, Clover Biopharmaceuticals Drops Over 14%

Tiger Newspress
·
Aug 27

Stock Track | KEYMED BIO-B Soars 5.09% as CICC Raises Target Price by 54.5% to HK$85.00

Stock Track
·
Aug 27

CICC Maintains Outperform Rating on KEYMED BIO-B (02162), Raises Target Price to HK$85.00

Stock News
·
Aug 27

Keymed Biosciences Narrows Loss in H1; CFO Steps Down

MT Newswires Live
·
Aug 26

KEYMED BIO-B (02162) Reports Interim Results with Shareholder Loss of RMB 78.84 Million, Narrowing by 76.59% Year-on-Year

Stock News
·
Aug 26

KeyMed Biosciences H1 Revenue RMB 169 Million

THOMSON REUTERS
·
Aug 26

Keymed Biosciences Inc. Conducted Annual General Meeting

Reuters
·
Jun 26

Keymed Biosciences Raises HK$853.8 Million from Top-Up Placement

MT Newswires Live
·
Jun 19